1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
2020 Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

2020 Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

  • February 2020
  • 112 pages
  • ID: 5863919
  • Format: PDF
  • VPAResearch

Summary

Table of Contents

The 2020 Neuromyelitis Optica (Devic’s Syndrome) pipeline report presents a comprehensive overview of the research and development of Neuromyelitis Optica (Devic’s Syndrome) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Research phase, Ten drugs in pre-clinical phase, six drugs in Phase 1, one drug in Phase 2, four drugs in Phase 3 and one drug pre-registration

As of February 2020, the Neuromyelitis Optica (Devic’s Syndrome) pipeline remains robust with 26 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Neuromyelitis Optica (Devic’s Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Anti-FcRn fully human monoclonal antibody; B lymphocyte stimulator inhibitor; CD19 antigen inhibitors; CD20 antigen inhibitors; Complement C3 inhibitor; Complement C5 inhibitors; Cytotoxic T lymphocyte stimulants; Estrogen receptor agonists; Interleukin 6 receptor antagonists; Monoacylglycerol lipase inhibitors; NF-kappa B inhibitors; RGMA protein inhibitors; Serum-glucocorticoid regulated kinase stimulants; STAT3 transcription factor inhibitors; Steroid receptor agonists; T lymphocyte stimulants; Th17 cell modulators; RORgt antagonist.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Neuromyelitis Optica (Devic’s Syndrome) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:
• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Neuromyelitis Optica (Devic’s Syndrome) development
• Neuromyelitis Optica (Devic’s Syndrome) pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Neuromyelitis Optica (Devic’s Syndrome) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Neuromyelitis Optica (Devic’s Syndrome) pipeline candidates included
• Business overview and snapshot of all companies involved in Neuromyelitis Optica (Devic’s Syndrome) pipeline are included
• Latest market and pipeline developments are provided in the report

Neuromyelitis Optica (Devic’s Syndrome) pipeline companies included in the report are- Accendatech Au Pty Ltd, Ahead Therapeutics SL, Alexion Pharmaceuticals Inc, Biogen Inc, Bionure Farma SL, Bio-Thera Solutions Ltd, Boston Pharmaceuticals Inc, Chord Therapeutics Sarl, Chugai Pharmaceutical Co Ltd, Cour Pharmaceuticals Development Co Inc, Endece LLC, EnhanX Biopharm Inc, Ferring International Center SA, H. Lundbeck AS, HanAll Biopharma Co Ltd, ImCyse SA, Imstem Biotechnology Inc, Mitsubishi Tanabe Pharma Corp, NovelMed Therapeutics Inc, Orion BioScience Inc, TG Therapeutics Inc, Tolerion Inc, Viela Bio Inc, Yantai RC-Pharmaceutical Co Ltd

Neuromyelitis Optica (Devic’s Syndrome) pipeline drugs profiled in the report include- ACT001, AT-1511, eculizumab, ravulizumab, rituximab, BN201, BAT4406F, ARN-6039 (BOS-172767), cladribine, SA237 (satralizumab), CNP-Aquaporin 4, NDC-1308, ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201), olamkicept (FE-301), ABX-1431, batoclimab, Synthetic Peptide for Neuromyelitis Optica, IMS001, IMS002, ublituximab, MT-3921, Complement C3-C5 inhibitors for Neuromyelitis Optica, ORNx-KI, TOL-3052, inebilizumab, telitacicept

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on